Regulatory and inspection intelligence, with the consequence attached
Guidance changes constantly and most summaries stop at describing the text. The useful part is what it means for a site with a lean quality team — and that is what this section is for.
Nothing is published here that is not traceable to an official source. No regulatory development is ever inferred, predicted or invented, and interpretation is always labelled as interpretation.
Four intelligence streams
Regulatory updates
Annex and chapter revisions, national guidance and MDR developments — what changed, who it applies to, and which documents at your site have to change.
Regulatory newsInspection intelligence
Recurring deficiency themes from published EU and FDA outcomes, grouped by quality-system area, with a note on which a self-inspection would have caught first.
BriefingsTrends and industry risk
Where exposure is concentrating across sectors — sterile, ATMP, devices, distribution — and what a mid-size site should be preparing for.
By sectorResearch and benchmarks
Aggregated, anonymised benchmark data, published only where the sample and methodology support a defensible conclusion.
ResearchThe format every briefing follows
An executive brief answers the same seven questions each time, so a reader can find the part relevant to their accountability without reading the whole thing. No briefing is listed until there is a genuine development to write about.
- 01What changedThe specific text, guidance or outcome, linked to the primary document.
- 02Why it mattersWho it applies to, transition dates, and whether it is urgent for a mid-size site.
- 03Business impactLicence, supply and commercial consequences, in executive language.
- 04Operational impactWhat changes on the floor, in the laboratory, or in the release path.
- 05Quality impactWhich procedures, records and validation positions are affected.
- 06What management should considerThe decisions this creates, and what can reasonably wait.
- 07Official sourcesDirect links to the regulator's own text, never a paraphrase presented as the requirement.
No executive briefings are published yet. This section shows the format rather than filling it with invented developments.
The authorities this section tracks
- European CommissionEudraLex Volume 4 — EU GMP guidelines
- EMAEuropean Medicines Agency
- ICHICH Quality guidelines (Q1–Q14)
- PIC/SPIC/S publications and guides
- MHRAMHRA — GxP Data Integrity Guidance and Definitions
- IGJ, NetherlandsInspectie Gezondheidszorg en Jeugd (IGJ)
- CBG-MEB, NetherlandsMedicines Evaluation Board (CBG-MEB)
- FDAFDA — Current Good Manufacturing Practice (CGMP) regulations
Get the update instead of checking back
A short monthly note, sent only when there is something worth sending. Roughly ten a year, no sequences, unsubscribe in one click.